Department of Biomedical Engineering, School of Medicine, Tsinghua-Peking Center for Life Sciences, Tsinghua University, Beijing, China.
Beijing CytoNiche Biotechnology Co. Ltd, Beijing, China.
J Tissue Eng Regen Med. 2022 Oct;16(10):934-944. doi: 10.1002/term.3341. Epub 2022 Aug 5.
Efficient and large-scale expansion of mesenchymal stem/stromal cells (MSCs) has always been a formidable challenge to researchers in cell-based therapies and regenerative medicine. To reconcile major drawbacks of 2D planar culturing system, we innovatively developed an automated closed industrial scale cell production (ACISCP) platform based on GMP-grade microcarrier for culture of umbilical cord-mesenchymal stem/stromal cells (UCMSCs), in accordance with the criteria of stem cell bank. ACISCP system is a fully closed system, which employs different models of vivaSPIN bioreactors (CytoNiche Biotech, China) for scale-up cell culture and vivaPREP (CytoNiche Biotech, China) for automated cell harvesting and cell dosage preparation. To realize industrial scale expansion of UCMSCs, a three-stage expansion was conducted with 1 L, 5 and 15 L vivaSPIN bioreactors. Using 3D TableTrix and ACISCP system, we inoculated 1.5 × 10 of UCMSCs into 1 L vivaSPIN bioreactor and finally scaled to two 15 L bioreactor. A final yield of 2.09 × 10 cells with an overall expansion factor of 1975 within 13 days. The cells were harvested, concentrated, washed and prepared automatically with vivaPREP. The entire process was realized with ACISCP platform and was totally enclosed. Critical quality attributes (CQA) assessments and release tests of MSCs, including sterility, safety, purity, viability, identity, stability and potency were performed accordingly. The quality of cells harvested from 3D culture on the ACISCP and conventional 2D planar culture counterpart has no significant difference. This study provides a bioprocess engineering platform, harnessing GMP-grade 3D TableTrix microcarriers and ACISCP to achieve industrial-scale manufacturing of clinical-grade hMSCs.
高效且大规模扩增间充质干细胞(MSCs)一直是细胞治疗和再生医学领域研究人员面临的巨大挑战。为了解决二维平面培养系统的主要缺点,我们创新性地开发了一种基于 GMP 级微载体的自动化封闭工业规模细胞生产(ACISCP)平台,用于培养脐带间充质干细胞(UCMSCs),符合干细胞库的标准。ACISCP 系统是一个完全封闭的系统,它采用不同型号的 vivaspin 生物反应器(CytoNiche Biotech,中国)进行规模放大细胞培养和 vivaprep(CytoNiche Biotech,中国)进行自动化细胞收获和细胞剂量制备。为了实现 UCMSCs 的工业规模扩增,我们进行了三阶段扩增,使用 1L、5L 和 15L vivaspin 生物反应器。使用 3D TableTrix 和 ACISCP 系统,我们将 1.5×10 的 UCMSCs 接种到 1L vivaspin 生物反应器中,最终扩大到两个 15L 生物反应器。最终收获到 2.09×10 个细胞,总扩增倍数为 1975 倍,耗时 13 天。细胞被收获、浓缩、洗涤,并通过 vivaprep 自动制备。整个过程都是在 ACISCP 平台上实现的,完全封闭。对 MSC 进行了关键质量属性(CQA)评估和放行试验,包括无菌性、安全性、纯度、活力、身份、稳定性和效力。从 ACISCP 和传统二维平面培养系统收获的细胞的质量没有显著差异。本研究提供了一个生物工艺工程平台,利用 GMP 级 3D TableTrix 微载体和 ACISCP 实现临床级 hMSCs 的工业规模制造。